Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...
Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...
Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, ...
As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...
Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...
5don MSN
Why Moderna Stock Surged Today
The vaccine maker is expanding beyond its COVID-focused offerings.
We learn what the findings could mean for fighting cancer ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
Jan 20 () - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results